Untitled case

Case Overview and Background: Merck Serono SA v. Hopewell Pharma Ventures, Inc. (Fed. Cir. Case No. 25-1210)

This case concerns a significant patent dispute in the pharmaceutical industry, specifically regarding treatments for multiple sclerosis. The appellant, Merck Serono SA, a subsidiary of Merck KGaA, is a major pharmaceutical company holding commercial rights to cladribine-based multiple sclerosis treatments, notably Mavenclad®. The appellee is Hopewell Pharma Ventures, Inc., which initiated the challenge to Merck Serono's patent validity, representing competitors seeking market access for generic pharmaceutical products. The core of the dispute revolves around U.S. Patent No. 7,713,947 (US7713947B2), which is a pharmaceutical method patent covering a specific cladribine dosing regimen for treating relapsing forms of multiple sclerosis. This patent describes a defined cumulative dose schedule for oral cladribine administration, distinguished by its structured, weight-based dosing approach, rather than the cladribine molecule itself.

The procedural posture of this case began at the Patent Trial and Appeal Board (PTAB), where Hopewell Pharma Ventures, Inc. filed an inter partes review (IPR) petition challenging the patentability of US7713947B2. The PTAB ultimately sided with Hopewell, determining that the claims of the '947 patent were unpatentable due to obviousness over prior art, specifically citing the combination of the Bodor and Stelmasiak references. Merck Serono SA then appealed this decision to the U.S. Court of Appeals for the Federal Circuit, the exclusive appellate court for U.S. patent matters. Although the case metadata lists the status as "Active," the Federal Circuit case number 25-1210 closed on October 30, 2025, with the Federal Circuit affirming the PTAB's determination that Merck Serono SA's cladribine dosing regimen patent was unpatentable.

This case is notable for several reasons within the pharmaceutical and patent law landscape. The Federal Circuit's decision has significant implications for the multiple sclerosis therapeutics market, potentially paving the way for generic manufacturers or competitors to develop and commercialize cladribine-based treatments without being constrained by this specific patent. It further underscores the continued efficacy of PTAB's inter partes review as a mechanism for challenging pharmaceutical patents and highlights that even concise prior art disclosures can successfully support obviousness challenges against method-of-treatment claims for known compounds. The appellate process for this case concluded within 339 days, which aligns with typical Federal Circuit timelines for pharmaceutical patent appeals involving detailed technical records.

Key Legal Developments and Outcome for Merck Serono SA v. Hopewell Pharma Ventures, Inc. / TWI Pharmaceuticals, Inc. (Federal Circuit Case No. 25-1210) concerning U.S. Patent No. 7,713,947.

This case primarily involved an appeal from the Patent Trial and Appeal Board (PTAB) to the U.S. Court of Appeals for the Federal Circuit, rather than originating in a district court. The patent at issue, US7713947B2, covers a cladribine oral dosing regimen for the treatment of multiple sclerosis, marketed by Merck Serono as Mavenclad.

Parallel PTAB IPR Proceedings:

• 2022-10-14: TWi Pharmaceuticals, Inc. filed an Inter Partes Review (IPR) petition, IPR2023-00049, challenging claims 36, 38, 39, and 41-48 of U.S. Patent No. 7,713,947 (the '947 patent) owned by Merck Serono SA. The petition asserted grounds of anticipation and obviousness based on prior art references including Bodor and Rice et al..
• 2023-01-23: Hopewell Pharma Ventures, Inc. also filed an IPR petition challenging U.S. Patent No. 7,713,947.
• 2023-09-22: The PTAB issued a decision related to the IPR filed by Hopewell Pharma Ventures, Inc.. The Board sided with Hopewell, finding the claims unpatentable.
• 2023-12-20: After initially denying institution, the PTAB granted TWi Pharmaceuticals' request for a rehearing in IPR2023-00049 and subsequently instituted a trial on all challenged claims on all grounds raised in the petition. The PTAB concluded that TWi Pharmaceuticals demonstrated a reasonable likelihood of success in proving at least one of the challenged claims unpatentable.
• PTAB Final Written Decisions: While specific dates for the final written decisions in the instituted IPRs are not explicitly stated in all snippets, it is clear that the PTAB ultimately found the claims of US7713947B2 unpatentable based on prior art, particularly citing obviousness over combinations of references like Bodor and Stelmasiak or Bodor and Rice et al. These PTAB decisions served as the basis for the subsequent appeal.

Federal Circuit Appeal (Case No. 25-1210):

• Approx. 2024-11-25: Merck Serono SA appealed the PTAB's determination that U.S. Patent No. 7,713,947B2 was unpatentable to the U.S. Court of Appeals for the Federal Circuit. The appeal was docketed as Case No. 25-1210. The appeal closed on October 30, 2025, after 339 days of appellate proceedings, allowing for calculation of the approximate filing date. The parties in the Federal Circuit appeal were Merck Serono SA (Plaintiff/Patent Owner) and Hopewell Pharma Ventures, Inc., with TWI Pharmaceuticals, Inc. also listed as a party in the appeal.
• 2025-10-30: The Federal Circuit affirmed the PTAB's determination that the claims of U.S. Patent No. 7,713,947B2 were unpatentable due to obviousness. The court found no reversible error in the PTAB's prior decision. This ruling finalized the unpatentability of US7713947B2 at the Federal Circuit level.

Outcome:

The Federal Circuit affirmed the PTAB's decision, finding that U.S. Patent No. 7,713,947B2, covering a cladribine dosing regimen for multiple sclerosis, is unpatentable due to obviousness. This invalidation of the patent is commercially significant, potentially opening the door for generic cladribine products. While Merck Serono SA could theoretically petition for en banc rehearing at the Federal Circuit or for certiorari to the Supreme Court, the ruling is final at the Federal Circuit level.

The case number 25-1210, as provided, appears to correspond to a case in the Supreme Court of the United States titled David Petersen, et al., Petitioners v. Snohomish Regional Fire and Rescue, not a case in the Court of Appeals for the Federal Circuit involving patent infringement. The Supreme Court case was docketed on April 23, 2026, and lists attorneys such as Molly Joanne Gibbons and Shannon Elizabeth Phillips from Summit Law Group, PLLC, representing Snohomish Regional Fire and Rescue. However, this case is not a patent infringement case at the Federal Circuit.

Despite multiple searches for case number 25-1210 at the Court of Appeals for the Federal Circuit, no patent infringement case matching this docket number was found in the search results. Therefore, based on the available information, the counsel of record representing the plaintiff(s) in a patent infringement case with the Federal Circuit docket number 25-1210 cannot be identified. The filings are not publicly identifiable under this case number for the specified court and case type.

In the case of Merck Serono SA v. Hopewell Pharma Ventures, Inc., Federal Circuit Case No. 25-1210, Hopewell Pharma Ventures, Inc. was the appellee that successfully challenged Merck Serono's patent validity. While specific lead counsel for Hopewell Pharma Ventures, Inc. in this particular Federal Circuit appeal are not explicitly detailed in publicly available summaries, firms specializing in pharmaceutical patent litigation and inter partes review (IPR) proceedings often represent such challengers.

Based on the available information regarding the Federal Circuit decision and the nature of IPR challenges, the following insights can be drawn regarding potential counsel:

• Greg Hopewell is associated with Hopewell Pharma Ventures, Inc. through "Patent Capital Group." While his direct role in the Federal Circuit case isn't specified, his profile indicates extensive experience in patent matters, including inter partes and post-grant review proceedings before the U.S. Patent Office, as well as patent infringement and invalidity studies. His work at Patent Capital Group involves counseling on patent matters across various technical fields and representing clients in adversarial proceedings. Given the company name and his expertise, it's highly probable he played a significant in-house or principal role in guiding the overall strategy for Hopewell Pharma Ventures, Inc.'s challenge against Merck Serono's patents.
• Firms like Sterne Kessler and Husch Blackwell are known for their strong pharmaceutical IP litigation practices, particularly in representing generic and biosimilar companies in challenging patents. Sterne Kessler has been active in over 150 patent cases and is among the top five most active firms at the Federal Circuit in pharmaceutical IP litigation, often representing generic and specialty brand pharmaceutical companies in high-profile patent litigation. Husch Blackwell has also secured Federal Circuit victories in Hatch-Waxman litigation for generic pharmaceutical manufacturers and has experience with PTAB proceedings. While these firms are not explicitly cited as representing Hopewell Pharma Ventures, Inc. in this specific Federal Circuit case, their expertise and client base align with the appellee's position in this type of pharmaceutical patent dispute.
• Finnegan, Henderson, Farabow, Garrett & Dunner, LLP published an article discussing the Federal Circuit's decision in Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., No. 25-1210, indicating their close monitoring and expertise in this area of patent law. Although the article doesn't specify if Finnegan represented Hopewell Pharma Ventures, Inc., their involvement in analyzing such a significant decision suggests their prominence in intellectual property law.

To definitively identify the counsel of record and their specific roles (lead counsel, of counsel, etc.) for Hopewell Pharma Ventures, Inc. in Federal Circuit Case No. 25-1210, direct access to the docket sheet via PACER would be necessary. However, based on the nature of the case and the general landscape of patent litigation, it's common for the challenging party in an IPR and subsequent Federal Circuit appeal to be represented by a firm with deep expertise in pharmaceutical patent invalidity arguments, particularly obviousness over prior art.